- |||||||||| AM 1476 / AnaMar
AM1476 (South Hall 2B) - Feb 13, 2024 - Abstract #SSWC2024SSWC_446;
Amelioration of several processes related to fibroblast and macrophage activation was observed. The highly selective 5-HT2B receptor antagonist AM1476, represents a promising drug candidate for treatment of fibrotic conditions and is currently in phase II development for systemic sclerosis.
- |||||||||| AM 1476 / AnaMar
Enrollment change: Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects (clinicaltrials.gov) - May 17, 2023
P1, N=97, Completed,
The highly selective 5-HT2B receptor antagonist AM1476, represents a promising drug candidate for treatment of fibrotic conditions and is currently in phase II development for systemic sclerosis. N=72 --> 97
- |||||||||| AM 1476 / AnaMar
Trial completion, Trial completion date, Trial primary completion date: Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects (clinicaltrials.gov) - Feb 16, 2022
P1, N=72, Completed,
N=72 --> 97 Recruiting --> Completed | Trial completion date: Jun 2021 --> Jan 2022 | Trial primary completion date: Jun 2021 --> Jan 2022
|
